
Clinica Chimica Acta 428 (2014) 1–8

Contents lists available at ScienceDirect

**Clinica Chimica Acta**

journal homepage: www.elsevier.com/locate/clinchim

---

**Invited critical review**

# Apelin and its receptor APJ in cardiovascular diseases

Xiao-Hua Yu ${ }^{a}$, Zhi-Bin Tang ${ }^{c}$, Li-Jing Liu ${ }^{d}$, Hong Qian ${ }^{d}$, Shi-Lin Tang ${ }^{c}$, Da-Wei Zhang ${ }^{e}$, Guo-Ping Tian ${ }^{f,1}$, Chao-Ke Tang ${ }^{a,b,2}$

${ }^{a}$ Life Science Research Center, University of South China, Hengyang, Hunan 421001, China  
${ }^{b}$ Institute of Cardiovascular Research, Key Laboratory for Atherosclerosis of Hunan Province, University of South China, Hengyang, Hunan 421001, China  
${ }^{c}$ Department of Orthopedics, The First Affiliated Hospital, University of South China, Hengyang, Hunan 421001, China  
${ }^{d}$ Department of Clinical Medicine, Huaihua Medical College, Huaihua, Hunan 418000, China  
${ }^{e}$ Department of Pediatrics and Group on the Molecular and Cell Biology of Lipids, University of Alberta, Edmonton, Alberta T6G 2S2, Canada  
${ }^{f}$ Department of Cardiovascular Medicine, The Second Affiliated Hospital, University of South China, Hengyang 421001, Hunan, China

---

## Article Info

### Article history:
- Received 6 July 2013
- Received in revised form 31 August 2013
- Accepted 1 September 2013
- Available online 18 September 2013

### Keywords:
- Apelin
- APJ
- Atherosclerosis
- CAD
- Heart failure
- Hypertension

---

## Abstract

Apelin is an adipokine that has been identified as an endogenous ligand for the orphan receptor APJ. Apelin and APJ are expressed in a diverse range of tissues with particular preponderance for the heart and vasculature. Apelin has powerful positive inotropic actions and causes endothelium- and nitric oxide-dependent vasodilation. Growing evidence shows that apelin/APJ system functions as a critical mediator of cardiovascular homeostasis and is involved in the pathophysiology of cardiovascular diseases. Targeting apelin/APJ axis produces protection against cardiovascular diseases. In the current review we have summarized recent data concerning the role and therapeutic potential of apelin/APJ in several major cardiovascular diseases. An increased understanding of the cardiovascular actions of apelin/APJ system will help to develop novel therapeutic interventions for cardiovascular diseases.

© 2013 Elsevier B.V. All rights reserved.

---

## Contents

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7. Conclusion and future directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
X.-H. Yu et al. / Clinica Chimica Acta 428 (2014) 1–8

![Diagram](attachment:diagram.png)

Fig. 1. Schematic of apelin/APJ-triggered intracellular signal transduction pathways. Apelin can induce VSMC proliferation by activating ERK/Jagged-1/Notch3/Cyclin D1 signaling pathway. Apelin inhibits TNF-α-induced reduction of glycogen synthesis through improving JNK/IRS1/GSK signaling in HepG2 cells. Apelin promotes Fas-induced hepatocyte apoptosis in a JNK-dependent mechanism but prevents human VSMC apoptosis via PI3K/Akt-induced increase in the ratio of Bcl-2 to Bax. Apelin/APJ significantly increases the expression of ICAM-1, VCAM-1 and MCP-1 in human umbilical vein endothelial cells through G-Protein/NF-κB/JNK pathway yet reduces MCP-1 expression in endothelial cells through activation of PI3K/Akt/Smad3. Treatment of primary amnion cells with apelin decreases IL-1β-induced IL-6 and IL-8 secretion as well as COX-2-mediated PGE2 release. The apelin/APJ axis stimulates KLF2 transcription in endothelial cells through inhibition of HDAC 4 and HDAC5 phosphorylation and subsequent upregulation of MEF2 expression. Apelin also suppresses lipolysis of mature adipocytes via AMPK-dependent enhancement of perilipin levels. Additionally, apelin increases the synthesis of VEGFA and PDGF-BB by inducing Ang-1 expression in HepG2 cells. P: phosphorylation.

hypotensive effect of apelin [26]. Injection of apelin into the ischemic myocardium facilitates neovascularization in the peri-infarct area through paracrine activity [27]. Treatment with apelin also decreases systemic venous tone [28], and inhibits arginine vasopressin release to promote diuresis [29]. On the other hand, intraperitoneal injection of apelin reduces left ventricular preload and afterload without causing cardiac hypertrophy [30]. In a study of isolated perfused rat hearts, apelin is identified as one of the most potent endogenous positive inotropic substances [31]. Moreover, isolated left ventricular cardiomyocytes lacking either apelin or APJ display less sarcomeric shortening and impaired velocity of contraction and relaxation with no difference in calcium transient [32]. These findings indicate an important role for apelin/APJ system in maintaining basal cardiac function.

5. Roles of apelin and APJ in cardiovascular diseases

5.1. Atherosclerosis

Atherosclerosis is a complex, chronic inflammatory disease of the vessel wall with lipid-laden lesions. Formation of macrophage foam cells in the intima is a major hallmark of early stage atherosclerotic lesions. Uncontrolled uptake of oxidized low-density lipoprotein (ox-LDL) via CD36, excessive cholesterol esterification by acyl coenzyme A:cholesterol acyltransferase 1 (ACAT1) and/or impaired cholesterol efflux mediated by ATP-binding cassette transporter A1 (ABCA1) result in the accumulation of cellular cholesterol ester, which subsequently triggers the formation of foam cells [33]. Studies from our laboratory revealed that apelin-13, the predominant apelin isoform in circulatory system, significantly promotes intracellular cholesterol efflux and reduces macrophage foam cell formation by increasing ABCA1 protein levels, indicating an potential antiatherogenic function of apelin-13 [34]. Mechanistically, the regulation of ABCA1 expression by apelin-13 is through activating the PKCα pathway and inhibiting calpain activity [34]. However, it remains unclear whether apelin modulates CD36 and ACAT1 expression. The influence of apelin on lipid metabolism may become an important research topic in the future.

The precise role of apelin and APJ in protecting against the development of atherosclerosis remains uncertain (Table 1). Rittig et al. observed that plasma apelin levels are not associated with early stages of atherosclerosis in young subjects prone to atherosclerosis and type 2 diabetes [35]. Nevertheless, Kadoglou and colleagues have demonstrated that patients with carotid atherosclerosis show lower apelin levels as compared to healthy controls, and apelin increment is independently associated with the atorvastatin-induced increase of gray-scale median

![Cardiovascular Diagram](attachment:cardiovascular_diagram.png)

Fig. 2. Cardiovascular physiological actions of apelin/APJ system.

Table 1  
Effects of apelin/APJ system on cardiovascular diseases.

| Disease types       | Experiment models                                                                 | Pathway                                                                                   | Action      | Ref.         |
|---------------------|----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------|--------------|
| Atherosclerosis     | THP-1 macrophage-derived foam cells                                              | ↑PKCα/ABCA1, ↓calpain                                                                     | Protection  | [34]         |
|                     | Human plasma                                                                    | ?                                                                                        | No          | [35]         |
|                     | Human plasma                                                                    | ?                                                                                        | Protection  | [36,37]      |
|                     | Mice in vivo                                                                    | ↑NO, ↓Ang II                                                                             | Protection  | [38]         |
|                     | Mice in vivo knockout                                                          | ↓Superoxide radicals, ↓NADPO                                                              | Protection  | [39]         |
| CAD                 | Human in vivo                                                                  | ?                                                                                        | Promotion   | [40,41]      |
|                     | Human in vivo (gene studies)                                                   | ?                                                                                        | Protection  | [42]         |
|                     | Human plasma                                                                   | ?                                                                                        | Protection  | [43–48]      |
|                     | Rats in vivo (coronary ligation)                                                | ↓oxidative injury, ↑NO                                                                    | Protection  | [49]         |
|                     | Mice in vivo (coronary ligation)                                                | ↑SDF-1α/CXCR-4, ↑PCs                                                                      | Protection  | [50]         |
|                     | Rats in vivo (coronary ligation)                                                | ?                                                                                        | Protection  | [51]         |
|                     | Rats in vivo (coronary occlusion)                                               | ?                                                                                        | Protection  | [52]         |
| Heart failure       | Rats in vivo                                                                   | ?                                                                                        | Protection  | [53]         |
|                     | Mice in vivo knockout                                                          | ↑Systolic dysfunction                                                                     | Promotion   | [54]         |
|                     | Mice in vivo knockout                                                          | ↓β-arrestins                                                                              | Protection  | [55]         |
|                     | Human in vivo                                                                  | ?                                                                                        | Protection  | [56,57]      |
|                     | Human plasma                                                                   | ?                                                                                        | Protection  | [58,59]      |
|                     | Mice in vivo/in vitro (cardiac fibroblasts)                                     | ↓TGF-β, ↓SphK1                                                                            | Protection  | [62]         |
|                     | Human in vivo                                                                  | ↑Vasodilatation, ↑LVEF                                                                    | Protection  | [63,66]      |
|                     | Rats in vivo                                                                   | ↓Cardiac dysfunction                                                                     | Protection  | [64,65]      |
| Hypertension        | Human plasma                                                                   | ?                                                                                        | Protection  | [67–69]      |
|                     | Human in vivo                                                                  | ?                                                                                        | Protection  | [70]         |
|                     | Human in vivo (gene studies)                                                   | ?                                                                                        | Protection  | [71]         |
|                     | Rats in vivo                                                                   | ↓RAS                                                                                     | Protection  | [72,73]      |
|                     | Rats ex vivo (aorta)                                                           | ↑L-Arg/NOS/NO                                                                            | Protection  | [74]         |
|                     | Rats in vivo                                                                   | ?                                                                                        | Promotion   | [75]         |
|                     | Mice in vivo                                                                   | ?                                                                                        | Promotion   | [76]         |
| PAH                 | Human plasma/mice in vivo knockout                                              | ↓AMPK, ↓KLF2/eNOS                                                                        | Promotion   | [77]         |
|                     | Human in vitro (PAECs)/mice in vivo                                             | ?                                                                                        | Protection  | [78]         |
|                     | Rats in vivo                                                                   | ↓BNP, ↓AGT, ↓ET-1                                                                         | Protection  | [79]         |
|                     | Human in vitro (PAECs)/mice in vivo                                             | ↑miRNA/FGF2                                                                              | Protection  | [80]         |
| MI/R/I              | Rats ex vivo (hearts)                                                          | ?                                                                                        | Protection  | [82]         |
|                     | Rats in vivo                                                                   | ↑PI3K/Akt, ↑AMPK, ↑ERK                                                                    | Protection  | [83]         |
|                     | Rats ex vivo (hearts)/myocardial cells                                          | ↓ROS, ↓MDA, ↓LDH                                                                          | Protection  | [84]         |
|                     | Mice/rats in vivo/myocardial cells                                              | ↑RISK, ↓MPTP opening                                                                      | Protection  | [85]         |
| Atrial fibrillation | Human plasma                                                                   | ?                                                                                        | Protection  | [87,88,90]   |

↑ indicates activation or promotion. ↓ indicates inhibition.
in the repair of diabetic mouse infarcted hearts through upregulation of apelin expression [52]. However, apelin protection against CAD has not been tested in humans. This promising effect of apelin can be applied in humans in the conditions that myocardial infarction severely impairs the heart function, the most common cause of heart failure. Application of apelin during the percutaneous coronary intervention may have therapeutic benefits as well.

### 5.3. Heart failure

There is increasing interest about the role of apelin and its receptor APJ in heart failure development (Table 1). In murine model of hypertensive heart disease, the expression of cardiac apelin and APJ shows no change at the stage of compensatory left ventricular hypertrophy but is markedly decreased at the stage of heart failure [53]. Apelin-deficient mice develop progressive heart failure associated with systolic dysfunction [54], but mice lacking APJ confer resistance to heart failure by inhibiting the expression of β-arrestins, suggesting an apelin-independent function of APJ [65]. In humans, myocardial apelin and APJ expression is downregulated in subjects with heart failure [56,57]. In addition, several groups have reported that plasma apelin levels are significantly lower in patients with heart failure compared with age-matched controls, suggesting that reduced levels of plasma apelin may act as a reliable biomarker for detecting heart failure [58,59]. Recently, a variety of mechanisms have been proposed to explain how apelin reduction causes heart failure. Apelin can lower left ventricular preload and afterload in mice [30], and has strong positive inotropic effects [31,60]. In anesthetized rats, microinjection of apelin into subforrnal organ reduces blood pressure and heart rate [61]. Activation of cardiac fibroblasts and their differentiation into myofibroblasts are critical events in the progression of cardiac fibrosis that results in end-stage heart failure. Pchejetski et al. showed that apelin prevents TGF-β-induced activation of cardiac fibroblasts and collagen production by decreasing sphingosine kinase 1 (SphK1) activity [62]. They also demonstrated that apelin administration during the phase of reactive fibrosis inhibits structural remodeling of the myocardium and ventricular dysfunction, revealing a novel link between cardiac fibrosis and heart failure [62]. However, more mechanistic studies are necessary to elucidate the effects of apelin/APJ system on the pathology of heart failure.

Based on the cardioprotective actions of apelin and APJ, strategies to enhance apelin signaling may therefore help to retard the progression of heart failure. It has been reported that acute apelin administration causes peripheral and coronary vasodilation and increases cardiac output in patients with chronic heart failure [63]. Ang II receptor blocker olmesartan and exogenous apelin-13 significantly ameliorate cardiac dysfunction and remodeling in Dahl salt-sensitive hypertensive rats with end-stage heart failure through restoring apelin and APJ expression [64,65]. Intracoronary implantation of bone marrow mononuclear cells into ischemic hearts increases apelin levels and thereby contributes to the improvement of cardiac function in patients with severe heart failure [59]. In another study, prolonged 6-hour [Pyr¹]apelin-13 infusion leads to a sustained increase in cardiac index with increased left ventricular ejection fraction (LVEF) in patients with chronic heart failure, suggesting that APJ agonism may possess a major promise to complement current optimal medical therapy in chronic heart failure patients [66].

#### 5.4. Hypertension

Recently, a variety of studies have focused on the association of apelin/APJ system with hypertension (Table 1). Masked hypertension is a significant predictor of cardiovascular diseases, and plasma apelin levels are significantly lower in the masked hypertensive group as compared to normotensive controls [67]. In patients with essential hypertension, circulating apelin levels are also reduced and independently associated with more profound left ventricular systolic and diastolic

function impairment [68]. In addition, hypertensive rats show reduced plasma apelin levels and downregulation of APJ in kidneys [69]. Notably, APJ expression is remarkably downregulated in early-onset pregnancy-induced hypertension placentas, reflecting an aggravated placental condition with poor fetal growth [70]. The G212A allele of APJ exerts a protective effect against hypertension development [71]. It has been reported that apelin reduces blood pressure in deoxycorticosterone acetate-salt-induced hypertensive rats by inhibiting renin–angiotensin system (RAS) [72,73]. Jia and co-workers observed that apelin-induced vasodilation is directly associated with the activation of L-arginine (L-Arg)/nitric oxide synthase (NOS)/NO pathway in the incubated, isolated rat aorta [74]. On the other hand, the expression of apelin is significantly enhanced in the rostral ventrolateral medulla (RVLM) of spontaneously hypertensive rat when compared with normotensive rats [75]. Direct microinjection of exogenous apelin-13 into RVLM leads to chronic blood pressure elevation and cardiac hypertrophy in normotensive rats [75]. NG-nitro-L-arginine methyl ester (L-NAME), a potent endothelial NOS (eNOS) inhibitor, can induce hypertension. Apelin can transiently elevate blood pressure in L-NAME-treated mice although it decreases blood pressure in non-treated mice, indicating that apelin functions as a vasopressor peptide under pathological conditions [76]. Together, apelin may be used as a therapeutic agent in the treatment of hypertension in the future while we should pay attention to the complexity of regulation of blood pressure by apelin. Further researches are required to determine the precise role for apelin/APJ signaling in controlling blood pressure.

#### 5.5. PAH

PAH is a severe disease characterized by pulmonary vasoconstriction, pulmonary arterial remodeling, abnormal angiogenesis and impaired right ventricular function. Apelin and its receptor APJ are highly expressed in the pulmonary vasculature (Table 1). Chandra et al. reported that serum apelin levels of patients with pulmonary arterial hypertension are significantly decreased as compared to healthy controls, and apelin-null mice develop more severe pulmonary arterial hypertension due to reduced activation of AMPK and Krüppel-like factor 2 (KLF2)/eNOS [77]. Apelin expression is also downregulated in the pulmonary arterial endothelial cells (PAECs) of the patients with pulmonary arterial hypertension, and administration of apelin reverses PAH in mice with reduced production of apelin [78]. [Pyr¹]-apelin-13 administration has been shown to inhibit activation of several vasoconstrictors including type B natriuretic peptide (BNP), angiotensinogen (AGT) and endothelin-1 (ET-1) and thus retards the progression of right ventricular hypertrophy and diastolic dysfunction in rats with monocrotaline-induced pulmonary arterial hypertension [79]. Apelin deficiency leads to the hyperproliferation of PAECs and VSMCs via increased fibroblast growth factor 2 (FGF2) levels as a consequence of decreased expression of miR-424 and miR-503 that directly target FGF2 and downregulate its expression [80]. Reconstitution of miR-424 and miR-503 in vivo improves pulmonary arterial hypertension in experimental models, suggesting that apelin-dependent miRNA/FGF2 signaling axis plays a key role in the maintenance of pulmonary vascular homeostasis [80].

#### 5.6. MIRI

Apelin and APJ also involve in MIRI (Table 1) [81]. A recent study suggests that apelin mRNA is upregulated in ventricular myocardium from isolated rat hearts undergoing ischemia alone but markedly decreased after 30 min reperfusion while APJ mRNA levels have no change, and apelin administered during reperfusion significantly decreases infarct size in hearts subject to temporary coronary occlusion followed by reperfusion [82]. Administration of apelin-13 protects rat hearts against ischemia–reperfusion injury through inhibiting endoplasmic reticulum-dependent apoptosis via activation of PI3K/Akt, AMPK, and ERK [83]. Apelin treatment also significantly inhibits MIRI in rats through preventing the generation of reactive oxygen species
(ROS), malonaldehyde (MDA) content and lactate dehydrogenase (LDH) leakage [84]. Studies from Smith laboratory show that apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury by activating reperfusion injury salvage kinase (RISK) pathway and delaying mitochondrial permeability transition pore (MPTP) opening [85]. Collectively, apelin/APJ has protective effects in myocardial ischemia-reperfusion injury and may constitute an important therapy target.

### 5.7. Atrial fibrillation

Atrial fibrillation is one of the most common arrhythmias among cardiovascular disease patients. Apelin has increasingly been regarded as an important regulator of cardiovascular homeostasis with direct effects on cardiomyocyte contractility and electrophysiology (Table 1) [86]. Ellinor et al. reported that plasma levels of apelin are significantly lower in subjects with lone atrial fibrillation when compared with controls, representing a possible underlying diathesis predisposing to this common arrhythmia [87]. A recent study revealed that patients with plasma apelin levels below the median have a hazard ratio of 3.1 of atrial fibrillation recurrence with respect to those with high apelin levels [88]. Since brain natriuretic peptide (BNP) is one of the good biomarkers for atrial fibrillation [89], the authors also found that subjects with both low apelin and enhanced BNP possess a worse prognosis as compared to those with either low apelin or enhanced BNP alone [88]. Moreover, cardioversion of atrial fibrillation to sinus rhythm resulted in an increase of apelin and a decrease of BNP levels, whereas the patients who develop atrial fibrillation recurrence by the end of the follow-up period have similar values of apelin and BNP on final and initial evaluations [90]. Thus, low plasma apelin levels are an independent predictor for the recurrence and prognosis of atrial fibrillation. In addition to BNP, apelin may be of particular value for the identification of high-risk patients.

### 7. Conclusion and future directions

The discovery of the apelin/APJ axis is an exciting affair in cardiovascular research. Experimental and clinical investigations performed both in vivo and in vitro have suggested apelin/APJ as a critical mediator of cardiovascular homeostasis involved in the pathogenesis of several main cardiovascular diseases including atherosclerosis, CHD, heart failure, hypertension, PAH, MIRI and atrial fibrillation. However, the impact of apelin/APJ on atherosclerosis and hypertension is still controversial, and thus the contribution of the molecular pathway to disease protection in humans remains to be further explored. Although some synthetic agonists of APJ have therapeutic potential for reducing the risk of cardiovascular diseases [94–96], the safety and long-term effect of these agonists needs to be more fully characterized and better defined. In addition to these, there are still many problems left to be solved. How are apelin and APJ regulated in vivo? Are there any other components required for their function? Are there efficient approaches to enhance their cardiovascular physiological actions besides APJ agonists? What is the exact diagnostic and prognostic role of apelin/APJ in cardiovascular disease patients? In answering these and many other questions, we will assuredly strengthen our chances of developing apelin/APJ-based therapies to help further decrease cardiovascular disease risk in future generations.

### Conflict of interest

The authors have declared no conflict of interest.

### Acknowledgment

The authors gratefully acknowledge the financial support from the National Natural Sciences Foundation of China (81070220 and 81170278), and the Aid Program for Science and Technology Innovative Research Team in Higher Educational Institutions of Human Province, China (2008-244).

### References

[1] Cheng B, Chen J, Bai B, Xin Q. Neuroprotection of apelin and its signaling pathway. Peptides 2012;37:171–3.

[2] Lv D, Li H, Chen L. Apelin and APJ, a novel critical factor and therapeutic target for atherosclerosis. Acta Biochim Biophys Sin (Shanghai) 2013;45:527–33.

[3] Galanth C, Hus-Citharel A, Li B, Llorens-Cortes C. Apelin in the control of body fluid homeostasis and cardiovascular functions. Curr Pharm Des 2012;18:789–98.

[4] Tycinska AM, Lisowska A, Musial WJ, Sobkowicz B. Apelin in acute myocardial infarction and heart failure induced by ischemia. Clin Chim Acta 2012;413:406–10.

[5] Barnes G, Japp AG, Newby DE. Translational promise of the apelin–APJ system. Heart 2010;96:1011–6.

[6] Kalea AZ, Batlle D. Apelin and ACE2 in cardiovascular disease. Curr Opin Investig Drugs 2010;11:273–82.

[7] Geurts I, Lazarevic V, Derrien M, et al. Altered gut microbiota and endocannabinoid system tone in obese and diabetic leptin-resistant mice: impact on apelin regulation in adipose tissue. Front Microbiol 2011;2:149.

[8] Geiger K, Muendlein A, Stark N, et al. Hypoxia induces apelin expression in human adipocytes. Horm Metab Res 2011;43:380–5.

[9] Yamagata K, Tagawa C, Matsufuji H, Chino M. Dietary apigenin regulates high glucose and hypoxic reoxygenation-induced reductions in apelin expression in human endothelial cells. J Nutr Biochem 2012;23:929–36.

[10] Melgar-Lesmes P, Pauta M, Reichenbach V, et al. Hypoxia and proinflammatory factors upregulate apelin receptor expression in human stellate cells and hepatocytes. Gut 2011;60:1404–11.

[11] Than A, Tee WT, Chen P. Apelin secretion and expression of apelin receptors in 3T3-L1 adipocytes are differentially regulated by angiotensin type 1 and type 2 receptors. Mol Cell Endocrinol 2012;351:296–305.

[12] Poirier O, Ciumas M, Eyries M, Montagne K, Nadaud S, Soubrier F. Inhibition of apelin expression by BMP signaling in endothelial cells. Am J Physiol Cell Physiol 2012;303: C1139–45.

[13] Krist J, Wieder K, Kloting N, et al. Effects of weight loss and exercise on apelin serum concentrations and adipose tissue expression in human obesity. Obes Facts 2013;6:57–69.

[14] Lim R, Barker G, Riley C, Lappas M. Apelin is decreased with human preterm and term labor and regulates prolabor mediators in human primary amnion cells. Reprod Sci 2013;20:957–67.

[15] Li L, Xie F, Zhang Z, et al. Jagged-1/Notch3 signaling transduction pathway is involved in apelin-13-induced vascular smooth muscle cells proliferation. Acta Biochim Biophys Sin (Shanghai) 2013 [Epub ahead of print].

[16] Lu Y, Zhu X, Liang GX, et al. Apelin–APJ induces ICAM-1, VCAM-1 and MCP-1 expression via NF-kappaB/JNK signal pathway in human umbilical vein endothelial cells. Amino Acids 2012;43:2125–36.

[17] Kasai A, Ishimaru Y, Higashino K, et al. Inhibition of apelin expression switches endothelial cells from proliferative to mature state in pathological retinal angiogenesis. Angiogenesis 2013;16:723–34.

[18] Chu J, Zhang H, Huang X, et al. Apelin ameliorates TNF-alpha-induced reduction of glycogen synthesis in the hepatocytes through G protein-coupled receptor APJ. PLoS One 2013;8:e57231.

[19] Kang Y, Kim J, Anderson JP, et al. Apelin–APJ signaling is a critical regulator of endothelial MEF2 activation in cardiovascular development. Circ Res 2013;113:22–31.

[20] Than A, Cheng Y, Foh LC, et al. Apelin inhibits adipogenesis and lipolysis through distinct molecular pathways. Mol Cell Endocrinol 2012;362:227–41.

[21] Yasuzaki H, Yoshida S, Hashimoto T, et al. Involvement of the apelin receptor APJ in Fas-induced liver injury. Liver Int 2013;33:118–26.

[22] Cui RR, Mao DA, Yi L, et al. Apelin suppresses apoptosis of human vascular smooth muscle cells via APJ/PI3-K/Akt signaling pathways. Amino Acids 2010;39:1193–200.

[23] Lv SY, Yang YJ, Chen Q. Regulation of feeding behavior, gastrointestinal function and fluid homeostasis by apelin. Peptides 2013;44:87–92.

[24] Tatemoto K, Takayama K, Zou MX, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 2001;99:87–92.

[25] Ishida J, Hashimoto T, Hashimoto Y, et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 2004;279:26274–9.

[26] Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP. [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 2009;54:598–604.

[27] Tempel D, de Boer M, van Deel ED, et al. Apelin enhances cardiac neovascularization after myocardial infarction by recruiting aplnr+ circulating cells. Circ Res 2012;111:585–98.

[28] Cheng X, Cheng XS, Pang CC. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol 2003;470:171–5.

[29] De Mota N, Reaux-Le Goazigo A, El Messari S, et al. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci U S A 2004;101:10464–9.

[30] Ashley EA, Powers J, Chen M, et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 2005;65:73–82.

[31] Szokodi I, Tavi P, Foldes G, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002;91:434–40.

[32] Charo DN, Ho M, Fajardo G, et al. Endogenous regulation of cardiovascular function by apelin–APJ. Am J Physiol Heart Circ Physiol 2009;297:H1904–13.

[33] Yu XH, Fu YC, Zhang DW, Yin K, Tang CK. Foam cells in atherosclerosis. Clin Chim Acta 2013;424C:245–52.

[34] Liu XY, Lu Q, Ouyang XP, et al. Apelin-13 increases expression of ATP-binding cassette transporter A1 via activating protein kinase C alpha signaling in THP-1 macrophage-derived foam cells. Atherosclerosis 2013;226:398–407.

[35] Rittig K, Hildebrandt U, Thamer C, et al. Apelin serum levels are not associated with early atherosclerosis or fat distribution in young subjects with increased risk for type 2 diabetes. Exp Clin Endocrinol Diabetes 2011;119:358–61.

[36] Kadoglou NP, Sailer N, Mountzouoglou A, et al. Adipokines: a novel link between adiposity and carotid plaque vulnerability. Eur J Clin Invest 2012;42:1278–86.

[37] Kadoglou NP, Fotiadis G, Kapelouzou A, Kostakis A, Liapis CD, Vrabas IS. The differential anti-inflammatory effects of exercise modalities and their association with early carotid atherosclerosis progression in patients with Type 2 diabetes. Diabet Med 2013;30:e41–50.

[38] Chun HJ, Ali ZA, Kojima Y, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 2008;118:3343–54.

[39] Hashimoto T, Kihara M, Imai N, et al. Requirement of apelin–apelin receptor system for oxidative stress-linked atherosclerosis. Am J Pathol 2007;171:1705–12.

[40] Pitkin SL, Maguire JJ, Kuc RE, Davenport AP. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. Br J Pharmacol 2010;160:1785–95.

[41] Peltonen T, Napankangas J, Vuolteenaho O, et al. Apelin and its receptor APJ in human aortic valve stenosis. J Heart Valve Dis 2009;18:644–52.

[42] Jin W, Su X, Xu M, et al. Interactive association of five candidate polymorphisms in apelin/APJ pathway with coronary artery disease among Chinese hypertensive patients. PLoS One 2012;7:e51123.

[43] Weir RA, Chong KS, Dalzell JR, et al. Plasma apelin concentration is depressed following acute myocardial infarction in man. Eur J Heart Fail 2009;11:551–8.

[44] Ye J, Ni P, Kang L, Xu B. Apelin and vascular endothelial growth factor are associated with mobilization of endothelial progenitor cells after acute myocardial infarction. J Biomed Res 2012;26:400–9.

[45] Tycinska AM, Sobkowicz B, Mroczko B, et al. The value of apelin-36 and brain natriuretic peptide measurements in patients with first ST-elevation myocardial infarction. Clin Chim Acta 2010;411:2014–8.

[46] Kuklinska AM, Sobkowicz B, Sawicki R, et al. Apelin: a novel marker for the patients with first ST-elevation myocardial infarction. Heart Vessels 2010;25:363–7.

[47] Kadoglou NP, Lampropoulos S, Kapelouzou A, et al. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease — KOZANI STUDY. Transl Res 2010;155:238–46.

[48] Li Z, Bai Y, Hu J. Reduced apelin levels in stable angina. Intern Med 2008;47:1951–5.

[49] Azizi Y, Faghihi M, Imani A, Roghani M, Nazari A. Post-infarct treatment with [Pyr1]-apelin-13 reduces myocardial damage through reduction of oxidative injury and nitric oxide enhancement in the rat model of myocardial infarction. Peptides 2013;46:76–82.

[50] Li L, Zeng H, Chen JX. Apelin-13 increases myocardial progenitor cells and improves repair postmyocardial infarction. Am J Physiol Heart Circ Physiol 2012;303:H605–18.

[51] Pisarenko OI, Serebryakova LI, Pologeykina YA, et al. In vivo reduction of reperfusion injury to the heart with apelin-12 peptide in rats. Bull Exp Biol Med 2011;152:79–82.

[52] Zeng H, Li L, Chen JX. Overexpression of angiopoietin-1 increases CD133+/c-kit+ cells and reduces myocardial apoptosis in db/db mouse infarcted hearts. PLoS One 2012;7:e35905.

[53] Iwanaga Y, Kihara Y, Takenaka H, Kita T. Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of angiotensin II–angiotensin type 1 receptor system. J Mol Cell Cardiol 2006;41:798–806.

[54] Kuba K, Zhang L, Imai Y, et al. Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ Res 2007;101:e32–42.

[55] Scimia MC, Hurtado C, Ray S, et al. APJ acts as a dual receptor in cardiac hypertrophy. Nature 2012;488:394–8.

[56] Foldes G, Horkay F, Szokodi I, et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 2003;308:480–5.

[57] Chandrasekaran B, Kalra PR, Donovan J, Hooper J, Clague JR, McDonagh TA. Myocardial apelin production is reduced in humans with left ventricular systolic dysfunction. J Card Fail 2010;16:556–61.

[58] Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 2006;8:355–60.

[59] Gao LR, Xu RY, Zhang NK, et al. Increased apelin following bone marrow mononuclear cell transplantation contributes to the improvement of cardiac function in patients with severe heart failure. Cell Transplant 2009;18:1311–8.

[60] Berry MF, Pirolli TJ, Jayasankar V, et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 2004;110:II187–93.

[61] Dai L, Smith PM, Kuksis M, Ferguson AV. Apelin acts in the subfornical organ to influence neuronal excitability and cardiovascular function. J Physiol 2013;591:3421–32.

[62] Pchejetski D, Foussal C, Alfaroano C, et al. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J 2012;33:2360–9.

[63] Japp AG, Cruden NL, Barnes G, et al. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation 2010;121:1818–27.

[64] Fukushima H, Kobayashi N, Takeshima H, Koguchi W, Ishimitsu T. Effects of olmesartan on Apelin/APJ and Akt/endothelial nitric oxide synthase pathway in Dahl rats with end-stage heart failure. J Cardiovasc Pharmacol 2010;55:83–8.

[65] Koguchi W, Kobayashi N, Takeshima H, Ishikawa M, Sugiyama F, Ishimitsu T. Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circ J 2012;76:137–44.

[66] Barnes GD, Alam S, Carter G, et al. Sustained cardiovascular actions of APJ agonism during renin–angiotensin system activation and in patients with heart failure. Circ Heart Fail 2013;6:482–91.

[67] Papadopoulos DP, Mourouzis I, Faselis C, et al. Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels. J Clin Hypertens (Greenwich) 2013;15:333–6.

[68] Przewlocka-Kosmala M, Kotwica T, Mysiak A, Kosmala W. Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction. J Hypertens 2011;29:971–9.

[69] Najafipour H, Soltani Hekmat A, Nekooian AA, Esmaeili-Mahani S. Apelin receptor expression in ischemic and non-ischemic kidneys and cardiovascular responses to apelin in chronic two-kidney-one-clip hypertension in rats. Regul Pept 2012;178:43–50.

[70] Furuya M, Okuda M, Usui H, et al. Expression of angiotensin II receptor-like 1 in the placenta of pregnancy-induced hypertension. Int J Gynecol Pathol 2012;31:227–35.

[71] Falcone C, Bozzini S, Schirinzi S, et al. APJ polymorphisms in coronary artery disease patients with and without hypertension. Mol Med Rep 2012;5:321–5.

[72] Akcilar R, Turgut S, Caner V, et al. Apelin effects on blood pressure and RAS in DOCA-salt-induced hypertensive rats. Clin Exp Hypertens 2013 [Epub ahead of print].

[73] Kursunluoglu-Akcilar R, Kilic-Toprak E, Kilic-Erkek O, Turgut S, Bor-Kucukatay M. Apelin-induced hemorheological alterations in DOCA-salt hypertensive rats. Clin Hemorheol Microcirc 2013 [Epub ahead of print].

[74] Jia YX, Lu ZF, Zhang J, et al. Apelin activates l-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides 2007;28:2023–9.

[75] Zhang Q, Yao F, Raizada MK, O'Rourke ST, Sun C. Apelin gene transfer into the rostral ventrolateral medulla induces chronic blood pressure elevation in normotensive rats. Circ Res 2009;104:1421–8.

[76] Nagano K, Ishida J, Unno M, Matsukura T, Fukamizu A. Apelin elevates blood pressure in ICR mice with LNAME induced endothelial dysfunction. Mol Med Rep 2013;7:1371–5.

[77] Chandra SM, Razavi H, Kim J, et al. Disruption of the apelin–APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler Thromb Vasc Biol 2011;31:814–20.

[78] Alastalo TP, Li M, Perez Vde J, et al. Disruption of PPARgamma/beta-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest 2011;121:3735–46.
[79] Falcao-Pires I, Goncalves N, Henriques-Coelho T, Moreira-Goncalves D, Roncon-Albuquerque Jr R, Leite-Moreira AF. Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol 2009;296:H2007–14.

[80] Kim J, Kang Y, Kojima Y, et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med 2013;19:74–82.

[81] Smith CC, Yellon DM. Adipocytokines, cardiovascular pathophysiology and myocardial protection. Pharmacol Ther 2011;129:206–19.

[82] Kleinz MJ, Baxter GF. Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase. Regul Pept 2008;146:271–7.

[83] Tao J, Zhu W, Li Y, et al. Apelin-13 protects the heart against ischemia-reperfusion injury through inhibition of ER-dependent apoptotic pathways in a time-dependent fashion. Am J Physiol Heart Circ Physiol 2011;301:H1471–86.

[84] Zeng XJ, Zhang LK, Wang HX, Lu LQ, Ma LQ, Tang CS. Apelin protects heart against ischemia/reperfusion injury in rat. Peptides 2009;30:1144–52.

[85] Simpkin JC, Yellon DM, Davidson SM, Lim SY, Wynne AM, Smith CC. Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol 2007;102:518–28.

[86] Farkasfalvi K, Stagg MA, Coppen SR, et al. Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun 2007;357:889–95.

[87] Ellinor PT, Low AF, Macrae CA. Reduced apelin levels in lone atrial fibrillation. Eur Heart J 2006;27:222–6.

[88] Falcone C, Buzzi MP, D'Angelo A, et al. Apelin plasma levels predict arrhythmia recurrence in patients with persistent atrial fibrillation. Int J Immunopathol Pharmacol 2010;23:917–25.

[89] Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J 2013;34:1475–80.

[90] Kallergis EM, Manios EG, Kanoupakis EM, et al. Effect of sinus rhythm restoration after electrical cardioversion on apelin and brain natriuretic peptide prohormone levels in patients with persistent atrial fibrillation. Am J Cardiol 2010;105:90–4.

[91] Wang M, Gupta RC, Rastogi S, et al. Effects of acute intravenous infusion of apelin on left ventricular function in dogs with advanced heart failure. J Card Fail 2013;19:509–16.

[92] Kadoglou NP, Sailer N, Kapelouzou A, et al. Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes. Acta Diabetol 2012;49:269–76.

[93] Wang IN, Wang X, Ge X, et al. Apelin enhances directed cardiac differentiation of mouse and human embryonic stem cells. PLoS One 2012;7:e38328.

[94] Iturrioz X, Alvear-Perez R, De Mota N, et al. Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist. FASEB J 2010;24:1506–17.

[95] Wang W, McKinnie SM, Patel VB, et al. Loss of apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic apelin analogues. J Am Heart Assoc 2013;2:e000249.

[96] Pisarenko OI, Pologeykina YA, Bespalova Zh D, et al. Limitation of myocardial infarction by a structural analog of the peptide apelin-12. Dokl Biol Sci 2012;443:65–7.

[97] Jia ZQ, Hou L, Leger A, et al. Cardiovascular effects of a PEGylated apelin. Peptides 2012;38:181–8.

[98] Lambrecht NW, Yakubov I, Zer C, Sachs G. Transcriptomes of purified gastric ECL and parietal cells: identification of a novel pathway regulating acid secretion. Physiol Genomics 2006;25:153–65.